Memantine, an NMDA Receptor Antagonist, Attenuates Doxorubicin-Induced Cardiac Oxidative Stress and Inflammation in Mouse 4T1 Breast Cancer Model
Amirhosein Ghafouri-Asbagh, Koorosh Tabatabaei, Haleh Vaez, Ali Jafarizadeh, Hossein Saeedi, Behrooz Shokouhi, Behzad Baradaran · 2025
Read Memantine, an NMDA Receptor Antagonist, Attenuates Doxorubicin-Induced Cardiac Oxidative Stress and Inflammation in Mouse 4T1 Breast Cancer Model by Amirhosein Ghafouri-Asbagh, Koorosh Tabatabaei, Haleh Vaez, Ali Jafarizadeh, Hossein Saeedi, Behrooz Shokouhi, Behzad Baradaran (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12663047.txt.
Description
Amirhosein Ghafouri-Asbagh and co-authors test in 2025 whether a brain drug can shield the heart from a harsh cancer drug in mice. Doxorubicin is a mainstay against breast cancer but can injure the heart. Memantine, a drug that blocks a brain receptor, has shown hints of both tumor fighting and heart sparing effects.
The team grew breast tumors in mice and split them into four groups: no drug, memantine alone, doxorubicin alone, and both together. After a month, heart, liver, and lung tissue went under the microscope, and stress and inflammation markers were read in heart tissue. The pair outperformed doxorubicin alone on both fronts in the shown results: heart markers of oxidative stress and inflammation fell, and tumor cell death ran higher. The authors frame memantine as a partner that may let the cancer drug hit tumors while costing the heart less.
Catalog record
| CREATOR | Amirhosein Ghafouri-Asbagh, Koorosh Tabatabaei, Haleh Vaez, Ali Jafarizadeh, Hossein Saeedi, Behrooz Shokouhi, Behzad Baradaran |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 32 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |